GlassScriptPhysician profile
Allison P Young
NPI 1750501029
$7,725.36
in general payments reported to CMS, 2019-2025
27 companies · $1,999 in 2025
The $1,999 reported for 2025 was more than what 88% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $225 · 2021: $630 · 2022: $1,027 · 2023: $1,782 · 2024: $1,719 · 2025: $1,999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,474 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,474.06 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,296.82 | 2019-2025 | Rocklatan, Eysuvis, Centurion |
| Biotissue Holdings INC. | $1,121.78 | 2023-2025 | |
| Abbvie INC. | $731.80 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Rxsight INC | $507.57 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Sun Pharmaceutical Industries INC. | $482.42 | 2022-2025 | Cequa, Xelpros |
| Bausch & Lomb Americas INC. | $401.85 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Harrow Eye, LLC | $346.70 | 2024-2025 | Vevye |
| Allergan, INC. | $324.88 | 2019-2021 | |
| Amgen INC. | $313.68 | 2024-2025 | Tepezza |
| Oyster Point Pharma, INC. | $255.32 | 2023-2025 | Tyrvaya, Ryzumvi |
| Ocular Therapeutix, INC. | $253.21 | 2021-2024 | Dextenza |
| Aerie Pharmaceuticals, INC. | $252.16 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $202.11 | 2021-2022 | |
| Dompe US, INC. | $167.50 | 2021-2025 | Oxervate |
| Sight Sciences, INC. | $156.12 | 2025 | Omni Surgical System, Tearcare System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $127.12 | 2024 | Izervay |
| Horizon Therapeutics Plc | $125.71 | 2023 | Tepezza |
| Apellis Pharmaceuticals, INC. | $124.99 | 2023 | Syfovre |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $112.34 | 2020-2021 | |
| Carl Zeiss Meditec, INC. | $110.27 | 2020 | |
| Lensar, INC. | $101.16 | 2025 | Lensar Laser System |
| Johnson & Johnson Surgical Vision, INC. | $60.01 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $52.22 | 2025 | Xdemvy |
| Thea Pharma INC. | $35.67 | 2022-2024 | Iyuzeh |
| Rayner Intraocular Lenses Limited | $25.55 | 2024 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Glaukos Corporation | $23.98 | 2025 | Kxl System (Not Refurbished), Photrexa Viscous and Photrexa |
| Kala Pharmaceuticals, INC. | $12.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.